Compare · AZZ vs EW
AZZ vs EW
Side-by-side comparison of AZZ Inc. (AZZ) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.
Summary
- AZZ operates in Industrials, while EW operates in Health Care - the two are in different parts of the market.
- EW is the larger of the two at $49.36B, about 11.2x AZZ ($4.42B).
- Over the past year, AZZ is up 31.8% and EW is up 12.0% - AZZ leads by 19.8 points.
- AZZ has been more active in the news (17 items in the past 4 weeks vs 7 for EW).
- EW has more recent analyst coverage (25 ratings vs 14 for AZZ).
- Company
- AZZ Inc.
- Edwards Lifesciences Corporation
- Price
- $147.10-2.59%
- $85.70-2.46%
- Market cap
- $4.42B
- $49.36B
- 1M return
- -4.08%
- -3.25%
- 1Y return
- +31.83%
- +12.04%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 17
- 7
- Recent ratings
- 14
- 25
AZZ Inc.
AZZ Inc. provides galvanizing and metal coating solutions, welding solutions, specialty electrical equipment, and engineered services to the power generation, transmission, distribution, refining, and industrial markets in the United States and internationally. The company operates through two segments, Infrastructure Solutions and Metal Coatings. The Metal Coatings segment offers hot dip galvanizing, powder coating, anodizing, plating, and other metal coating applications to the steel fabrication and other industries. It serves fabricators or manufacturers that provide services to the electrical and telecommunications, bridge and highway, petrochemical, and general industrial markets, as well as original equipment manufacturers. The Infrastructure Solutions segment provides products and services to support industrial and electrical applications. It offers custom switchgear, electrical enclosures, medium and high voltage bus ducts, explosion proof and hazardous duty lighting, nuclear safety-related equipment, and tubular products, as well as solutions and engineering resources to multi-national companies and small independent companies. This segment sells its products through internal sales force, manufacturers' representatives, distributors, and agents. The company was incorporated in 1956 and is headquartered in Fort Worth, Texas.
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest AZZ
- AZZ Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by AZZ Inc.
- AZZ Inc. Reports Fiscal Year 2027 First Quarter Results
- Director Berce Daniel E was granted 937 shares, increasing direct ownership by 2% to 59,290 units (SEC Form 4)
- Director Mcgough Ed was granted 937 shares, increasing direct ownership by 5% to 20,306 units (SEC Form 4)
- Director Grannum Clive A was granted 937 shares, increasing direct ownership by 9% to 11,145 units (SEC Form 4)
- Director Purvis Steven R. was granted 937 shares, increasing direct ownership by 4% to 23,862 units (SEC Form 4)
- Director Schapper Aaron M was granted 937 shares (SEC Form 4)
- Director Treadway Charles L. was granted 937 shares (SEC Form 4)
- Director Jackson Carol R was granted 937 shares, increasing direct ownership by 9% to 11,145 units (SEC Form 4)
Latest EW
- Edwards Lifesciences to Host Earnings Conference Call on July 23, 2026
- CVP, EMEACLA Bruls Annette covered exercise/tax liability with 109 shares, decreasing direct ownership by 0.53% to 20,628 units (SEC Form 4) (for withholding tax)
- CVP, Chief Financial Officer Mistras Theodora was granted 99,920 shares (SEC Form 4)
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $56,762 worth of shares (619 units at $91.70) as part of a pre-agreed trading plan (SEC Form 4)
- CVP, TAVR Lippis Daniel J. covered exercise/tax liability with 377 shares, decreasing direct ownership by 0.93% to 40,034 units (SEC Form 4) to cover taxes
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $56,577 worth of shares (619 units at $91.40) as part of a pre-agreed trading plan (SEC Form 4)
- Edwards’ Structural Heart Leadership Demonstrated Through Expanding Body of Scientific Evidence at New York Valves
- CEO Zovighian Bernard J sold $45,982 worth of shares (523 units at $87.92) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 11-K filed by Edwards Lifesciences Corporation
- SEC Form 11-K filed by Edwards Lifesciences Corporation